Jubilant Organosys seems to have identified the New Jersey based NYSE-listed life-sciences company, Cambrex, as one of its potential acquisition targets, as it looks for big buys in the US and Europe. The domestic integrated pharma player could unveil a bid with valuation more than USD 500 mn following a due diligence in the next 3-6 months.
Myiris